APO RESEARCH · REPORT
Acute Migraine Drugs
A migraine is an episodic and unpredictable headache disorder that presents with disabling attack. Migraine is one of the most frequent disabling neurological conditions with a major impact on the patient’s quality of life. Migraine has been described as a chronic disorder that characterized with attacks. Attacks are characterized by moderate–severe, often unilateral, pulsating headache attacks, typically lasting 4 to 72 hours.
Product & engineering
Understand the product.
A migraine is an episodic and unpredictable headache disorder that presents with disabling attack. Migraine is one of the most frequent disabling neurological conditions with a major impact on the patient’s quality of life. Migraine has been described as a chronic disorder that characterized with attacks. Attacks are characterized by moderate–severe, often unilateral, pulsating headache attacks, typically lasting 4 to 72 hours.
Selected research
Industry Research
Acute Migraine Drugs Industry Research Report 2026
Market perspective
A migraine is an episodic and unpredictable headache disorder that presents with disabling attack. Migraine is one of the most frequent disabling neurological conditions with a major impact on the patient’s quality of life. Migraine has been described as a chronic disorder that characterized with attacks. Attacks are characterized by moderate–severe, often unilateral, pulsating headache attacks, typically lasting 4 to 72 hours.
The top 3 manufacturers held about 29.5% of the market share in 2019, while top 5 hold 41.93%.
Report Scope
Read the full market overview
This report quantifies the global Acute Migraine Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Unit), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Unit) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Acute Migraine Drugs Market by Company
GSK
Teva
Pfizer
Novartis
Sun Pharma
Grunenthal
Endo Pharmaceuticals
Merck
J & J
Acute Migraine Drugs Segment by Type
Triptans
NSAIDs
Others
Acute Migraine Drugs Segment by Application
Hospital Pharmacies
Drug Stores
Acute Migraine Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Migraine Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Acute Migraine Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Migraine Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Acute Migraine Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Acute Migraine Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Acute Migraine Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Triptans
- NSAIDs
- Others
Applications
- Hospital Pharmacies
- Drug Stores
Companies covered
- GSK
- Teva
- Pfizer
- Novartis
- Sun Pharma
- Grunenthal
- Endo Pharmaceuticals
- Merck
- J & J
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Acute Migraine Drugs Market Size (2021-2032)
- 2.2.2 Global Acute Migraine Drugs Sales (2021-2032)
- 2.2.3 Global Acute Migraine Drugs Market Average Price (2021-2032)
- 2.3 Acute Migraine Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Triptans
- 2.3.3 NSAIDs
- 2.3.4 Others
- 2.4 Acute Migraine Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital Pharmacies
- 2.4.3 Drug Stores
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Acute Migraine Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Acute Migraine Drugs Sales (K Unit) of Manufacturers (2021-2026)
- 3.3 Global Acute Migraine Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Acute Migraine Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Acute Migraine Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Acute Migraine Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Acute Migraine Drugs, Product Type & Application
- 3.8 Global Manufacturers of Acute Migraine Drugs, Established Date
- 3.9 Global Acute Migraine Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 GSK
- 4.1.1 GSK Company Information
- 4.1.2 GSK Business Overview
- 4.1.3 GSK Acute Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 GSK Acute Migraine Drugs Product Portfolio
- 4.1.5 GSK Recent Developments
- 4.2 Teva
- 4.2.1 Teva Company Information
- 4.2.2 Teva Business Overview
- 4.2.3 Teva Acute Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Teva Acute Migraine Drugs Product Portfolio
- 4.2.5 Teva Recent Developments
- 4.3 Pfizer
- 4.3.1 Pfizer Company Information
- 4.3.2 Pfizer Business Overview
- 4.3.3 Pfizer Acute Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pfizer Acute Migraine Drugs Product Portfolio
- 4.3.5 Pfizer Recent Developments
- 4.4 Novartis
- 4.4.1 Novartis Company Information
- 4.4.2 Novartis Business Overview
- 4.4.3 Novartis Acute Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novartis Acute Migraine Drugs Product Portfolio
- 4.4.5 Novartis Recent Developments
- 4.5 Sun Pharma
- 4.5.1 Sun Pharma Company Information
- 4.5.2 Sun Pharma Business Overview
- 4.5.3 Sun Pharma Acute Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sun Pharma Acute Migraine Drugs Product Portfolio
- 4.5.5 Sun Pharma Recent Developments
- 4.6 Grunenthal
- 4.6.1 Grunenthal Company Information
- 4.6.2 Grunenthal Business Overview
- 4.6.3 Grunenthal Acute Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Grunenthal Acute Migraine Drugs Product Portfolio
- 4.6.5 Grunenthal Recent Developments
- 4.7 Endo Pharmaceuticals
- 4.7.1 Endo Pharmaceuticals Company Information
- 4.7.2 Endo Pharmaceuticals Business Overview
- 4.7.3 Endo Pharmaceuticals Acute Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Endo Pharmaceuticals Acute Migraine Drugs Product Portfolio
- 4.7.5 Endo Pharmaceuticals Recent Developments
- 4.8 Merck
- 4.8.1 Merck Company Information
- 4.8.2 Merck Business Overview
- 4.8.3 Merck Acute Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Merck Acute Migraine Drugs Product Portfolio
- 4.8.5 Merck Recent Developments
- 4.9 J & J
- 4.9.1 J & J Company Information
- 4.9.2 J & J Business Overview
- 4.9.3 J & J Acute Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 J & J Acute Migraine Drugs Product Portfolio
- 4.9.5 J & J Recent Developments
5 Global Acute Migraine Drugs Market Scenario by Region
- 5.1 Global Acute Migraine Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Acute Migraine Drugs Sales by Region: 2021-2032
- 5.2.1 Global Acute Migraine Drugs Sales by Region: 2021-2026
- 5.2.2 Global Acute Migraine Drugs Sales by Region: 2027-2032
- 5.3 Global Acute Migraine Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Acute Migraine Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Acute Migraine Drugs Revenue by Region: 2027-2032
- 5.4 North America Acute Migraine Drugs Market Facts & Figures by Country
- 5.4.1 North America Acute Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Acute Migraine Drugs Sales by Country (2021-2032)
- 5.4.3 North America Acute Migraine Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Acute Migraine Drugs Market Facts & Figures by Country
- 5.5.1 Europe Acute Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Acute Migraine Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Acute Migraine Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Acute Migraine Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Acute Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Acute Migraine Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Acute Migraine Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Acute Migraine Drugs Market Facts & Figures by Country
- 5.7.1 South America Acute Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Acute Migraine Drugs Sales by Country (2021-2032)
- 5.7.3 South America Acute Migraine Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Acute Migraine Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Acute Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Acute Migraine Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Acute Migraine Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Acute Migraine Drugs Sales by Type (2021-2032)
- 6.1.1 Global Acute Migraine Drugs Sales by Type (2021-2032) & (K Unit)
- 6.1.2 Global Acute Migraine Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Acute Migraine Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Acute Migraine Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Acute Migraine Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Acute Migraine Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Acute Migraine Drugs Sales by Application (2021-2032)
- 7.1.1 Global Acute Migraine Drugs Sales by Application (2021-2032) & (K Unit)
- 7.1.2 Global Acute Migraine Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Acute Migraine Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Acute Migraine Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Acute Migraine Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Acute Migraine Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Acute Migraine Drugs Value Chain Analysis
- 8.1.1 Acute Migraine Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Acute Migraine Drugs Production Mode & Process
- 8.2 Acute Migraine Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Acute Migraine Drugs Distributors
- 8.2.3 Acute Migraine Drugs Customers
9 Global Acute Migraine Drugs Analyzing Market Dynamics
- 9.1 Acute Migraine Drugs Industry Trends
- 9.2 Acute Migraine Drugs Industry Drivers
- 9.3 Acute Migraine Drugs Industry Opportunities and Challenges
- 9.4 Acute Migraine Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst